Jefferies upgrades Chemed to Buy and lifts price target to $620
+2 new sources since this summary was written
Jefferies raised its rating on Chemed Corp. (CHE) from Hold to Buy and increased the price target from $520 to $620, citing strong recent hospice growth and improving margins. The upgrade follows Chemed's Q2 adjusted earnings per share of $6.06 and revenue of $673.25 million, which beat analyst forecasts. Jefferies expects the company to beat guidance for Q4 and FY 2026 as earnings stability returns. UBS also initiated coverage with a Buy rating and a $650 target, projecting low double‑digit adjusted EPS growth.
Why it matters
Jefferies' note suggests roughly 22% upside from the current price, which could attract buying interest. UBS's higher target and growth outlook reinforce expectations of earnings expansion, potentially supporting the stock’s valuation.
Key facts
- 1Jefferies upgraded Chemed from Hold to Buy and raised its price target to $620 from $520. investing.com
- 2Chemed reported adjusted earnings per share of $6.06 for the second quarter. investing.com
- 3Chemed reported second‑quarter revenue of $673.25 million. investing.com
- 4Jefferies expects Chemed to beat guidance for Q4 and fiscal year 2026. investing.com
- 5UBS initiated coverage with a Buy rating and a price target of $650. investing.com
- 6UBS projects low double‑digit adjusted EPS growth of 19% in 2026 and 10% in 2027 and 2028. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.